CytoMed Therapeutics (NASDAQ:GDTC) Posts Quarterly Earnings Results

CytoMed Therapeutics (NASDAQ:GDTC) announced its quarterly earnings results on Wednesday. The company reported ($0.06) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.06 million for the quarter.

CytoMed Therapeutics Stock Down 13.9%

GDTC stock traded down $0.13 during mid-day trading on Wednesday, hitting $0.80. 717 shares of the company were exchanged, compared to its average volume of 226,870. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. CytoMed Therapeutics has a twelve month low of $0.68 and a twelve month high of $3.68. The firm has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $0.99.

Analyst Ratings Changes

A number of research analysts have commented on GDTC shares. Fundamental Research set a $4.16 price objective on CytoMed Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CytoMed Therapeutics in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, CytoMed Therapeutics presently has an average rating of “Hold” and an average price target of $4.16.

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.